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Abstract
Objectives:  To  verify  and  describe  the  main  events  related  to  the  diagnosis  and  management  of
chronic obstructive  pulmonary  diseases  in  children  (COPDC)  and  adolescents,  considering  the
interrelated  physiopathology,  genetic,  and  environmental  characteristics.
Sources:  Relevant  literature  from  PubMed  was  selected  and  reviewed.
Summary  of  the  ﬁndings:  COPDC  have  an  environmental  and/or  genetic  origin  and  its  manifes-
tation has  manifold  genotypes,  phenotypes,  and  endotypes.  Although  COPDC  has  no  cure,  it  can
be clinically  controlled.  Chronic  cough  is  the  main  symptom  and  bronchiectasis  can  be  present
in several  COPDC  patients.  The  management  of  COPDC  is  more  effective  if  based  on  guidelines
and when  treatment  regimen  adherence  is  promoted.  Oral  and  inhaled  corticosteroids,  bron-
chodilators,  inhaled  antibiotics,  and  treatment  of  pulmonary  exacerbation  (PE)  are  the  bases
of COPDC  management,  and  should  be  individualized  for  each  patient.
Conclusions:  Correct  diagnosis  and  knowledge  of  risk  factors  and  comorbidities  are  essential  in
COPDC management.  Procedures  and  drugs  used  should  be  based  on  speciﬁc  guidelines  for  each
COPDC case.  Treatment  adherence  is  critical  to  obtain  the  beneﬁts  of  management.  COPDC
clinical control  must  be  evaluated  by  the  decrease  in  PEs,  improved  quality  of  life,  reduction
of pulmonary  function  loss,  and  lung  structural  damage.  For  most  cases  of  COPDC,  monitoring
by interdisciplinary  teams  in  specialized  reference  centers  with  surveillance  strategies  and
continuous  care  leads  to  better  outcomes,  which  must  be  evaluated  by  decreasing  pulmonary
function damage  and  deterioration,  better  prognosis,  better  quality  life,  and  increased  life
expectancy.
© 2015  Published  by  Elsevier  Editora  Ltda.  on  behalf  of  Sociedade  Brasileira  de  Pediatria.
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Crianc¸a;
Doenc¸a pulmonar
obstrutiva  crônica;
Tosse  crônica
Doenc¸as pulmonares  obstrutivas  crônicas  na  crianc¸a
Resumo
Objetivos:  Veriﬁcar  e  descrever  os  principais  eventos  relacionados  ao  diagnóstico  e  manejo  das
doenc¸as pulmonares  obstrutivas  crônicas  em  crianc¸as  (DPOCC)  e  adolescentes,  tendo  em  vista
a ﬁsiopatologia,  características  genéticas  e  ambientais  inter-relacionadas.
Fonte dos  dados:  Revisão  na  base  de  dado  PUBMED  com  selec¸ão  de  referências  relevantes.
Síntese dos  dados: As  DPOCC  têm  origem  ambiental  e/ou  genética  e  se  manifestam  com  diver-
sos genótipos,  fenótipos  e  endótipos  e,  embora  possam  ser  controladas,  não  têm  cura.  O
principal sintoma  é  a  tosse  crônica  e  muitas  cursam  com  bronquiectasia.  O  manejo  tem  maior
eﬁcácia se  baseado  em  guidelines  e  se  a  adesão  ao  regime  terapêutico  for  estimulada  e  com-
provada. Corticóides  orais  e  inalatórios,  broncodilatadores,  antibióticos  inalados  e  tratamento
das exacerbac¸ões  pulmonares  (EP)  são  vigas  mestras  do  manejo  e  devem  ser  individualizados
para cada  DPOCC.
Conclusões:  Nas  DPOCC  é  fundamental  o  diagnóstico  correto,  conhecer  os  fatores  de  risco  e
comorbidades.  Os  procedimentos  e  os  medicamentos  devem  ser  baseados  em  guidelines  especí-
ﬁcos para  cada  DPOCC.  Adesão  ao  tratamento  é  fundamental  para  obter  os  benefícios  do
manejo. O  controle  deve  ser  avaliado  pela  diminuic¸ão  das  EP,  melhora  na  qualidade  de  vida
e reduc¸ão  da  evoluc¸ão  da  perda  da  func¸ão  e  dano  estrutural  pulmonar.  Para  a  maioria  das
DPOCC, o  acompanhamento  por  equipes  interdisciplinares  em  centros  de  referência  especial-
izados, com  estratégias  de  vigilância  e  acolhimento  contínuos,  conduz  a  melhores  desfechos
que devem  ser  avaliados  pela  diminuic¸ão  da  deteriorac¸ão  do  dano  e  da  func¸ão  pulmonar,  melhor
prognóstico,  melhor  qualidade  de  vida  e  aumento  da  expectativa  de  vida.
© 2015  Publicado  por  Elsevier  Editora  Ltda.  em  nome  da  Sociedade  Brasileira  de  Pediatria.
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hronic  obstructive  pulmonary  disease  (COPD)  is  typically
hown  in  the  literature  as  evidence,  in  most  cases,  of  the
amage  caused  by  smoking  in  adults  older  than  40  years.
ithout  any  direct  and  exclusive  association  with  active
ong-term  smoking,  several  chronic  obstructive  pulmonary
iseases  in  children  (COPDC)  and  adolescents  progress  with
eterioration  in  lung  structure  and  function,  causing  per-
istent  (ﬁxed)  or  intermittent  (temporary)  obstruction  to
ulmonary  ﬂow,  secondary  to  genetic  and/or  environmental
hanges  that  cause  airway  inﬂammation  and/or  infection.
lthough  the  symptoms  of  COPDC  are  very  similar,  they  have
ariable  etiology,  morbidity,  physiopathology,  prevalence,
rognosis,  genotypes,  and  phenotypes.1,2
While  some  COPDC  have  been  the  object  of  many  studies,
uch  as  asthma,  cystic  ﬁbrosis  (CF),  recurrent  wheezing  in
nfants  (RWI),  and  bronchopulmonary  dysplasia  (BPD),  others
re  known  as  ‘‘orphan  diseases,’’  such  as  primary  ciliary
yskinesia  (PCD),  non-cystic  ﬁbrosis  bronchiectasis  (NCFB),
lastic  bronchitis  (PB),  and  bronchiolitis  obliterans  (BO).
COPDC  are  characterized  by  high  prevalence  of  asthma,
WI,  and  BPD,  or  low  prevalence  of  BO,  CF,  PB,  PCD,  and
CFB.  They  are  noncommunicable  diseases,  of  long  duration
nd  slow  progression,  showing  episodes  of  pulmonary  exac-
rbation  (PE),  acute  or  permanent  airﬂow  limitation,  and
igniﬁcant  quality  of  life  impairment.3 In  all,  the  main  pul-
onary  symptom  is  chronic  cough,  reﬂecting  the  presence
f  alterations  in  the  airways,  as  there  are  no  cough  recep-
ors  in  the  alveoli.  Another  characteristic  is  the  presence  of
ronchiectasis  in  many  of  them.4
Most  of  them,  including  some  of  the  several  clinical  forms
f  asthma,  course  with  neutrophilic  airway  inﬂammation,
n
mhich  contributes  to  progressive  worsening  of  pulmonary
amage  and  function  by  releasing:  (i)  elastase:  cleaves
lastin  and  causes  bronchiectasis,  decreases  opsonization
nd  phagocytosis,  increases  secretion,  decrease  mucociliary
learance;  (ii)  DNA:  increases  the  viscosity  of  secretions;  (iii)
ydrogen  peroxide  and  other  oxidants:  causes  tissue  damage
nd  inactivates  -1-antitrypsin;  (iv)  IL-8  and  LTB4:  attract
ore  neutrophils.5
Two  aspects  of  COPDC  have  been  thoroughly  studied:  the
enetic  component  and  environmental  aggressions  that  initi-
te  or  exacerbate  the  diseases.  Most  COPDC  show  different
enotypes,  phenotypes,  endotypes,  and  degrees  of  sever-
ty,  require  different  types  of  management,  and  have  no
ure.6
Pneumonia,  BPD,  BO,  and/or  RWI  in  the  ﬁrst  years  of  life
onstitute  risk  groups  for  COPD  in  the  long  term  and  should
eceive  medical  follow-up  and  interventions  to  prevent  the
otential  impact  on  long-term  respiratory  sequelae.7--9
In  all  COPDC,  PE  is  often  triggered  by  viral  and/or
acterial  infections,  pollution,  and  aeroallergens.  The  PE
anifests  as  acute  respiratory  failure  of  varying  intensity,
oth  in  asthma  and  RWI,  and  as  increased  cough  and  chronic
nfection  in  CF,  BPD,  NCFB,  and  PCD.  The  signs  and  symptoms
f  PE  are  more  frequent  and  intense  at  nighttime.
While  the  majority  of  acute  respiratory  diseases  can  be
iagnosed  easily  and  efﬁciently  through  history  and  physi-
al  examination,  those  with  a  chronic  nature  may  require
ophisticated  laboratory  tests.  Continuous  and  scheduled
valuations  by  interdisciplinary  health  teams  in  specialized
enters  are  required  for  effective  management,  better  prog-
osis,  and  improved  quality  of  life  in  COPDC.
Establishing  protocols  based  on  systematic  reviews,
eta-analyses,  and  guidelines  allows  for  gaining  control  of
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sChronic  obstructive  pulmonary  diseases  in  children  
the  signs  and  symptoms  of  COPDC.  Oral  and  (OC)  inhaled
corticosteroids  (IC),  mucolytics,  bronchodilators,  inhaled
antibiotics,  and  other  drugs  should  be  used  according  to
speciﬁc  guidelines  for  each  COPDC.
While  some  groups  of  drugs  are  widely  used,  with  vari-
able  degree  of  scientiﬁc  evidence,  such  as  bronchodilators
and  IC,  others,  such  as  long-term  macrolide  use,  are  more
controversial.  The  use  of  macrolides  in  COPDC  have  been
justiﬁed  by  the  anti-inﬂammatory  and  immunomodulatory
effect,  the  decrease  in  mucus  production,  and  neutrophil
elastase  inhibition,  in  addition  to  reducing  the  production
of  pro-inﬂammatory  mediators  (e.g.  IL8)  and  stimulating
phagocytosis  of  apoptotic  cells.10--14 Although  macrolides
have  shown  to  be  effective  in  patients  with  CF  and  other
COPDC,  and  have  shown  encouraging  in  vitro  effects,  their
use  in  other  COPDC  has  shown  to  be  less  effective  and
requires  further  studies.14
The  objective  of  this  review  was  to  assess  and  describe
the  main  events  related  to  the  diagnosis  and  management
of  COPDC,  considering  the  physiopathology  and  interrelated
genetic  and  environmental  characteristics.
Data sources
Review  of  the  PubMed  databases  with  selection  of  relevant
references.  The  following  descriptors  were  used  (according
to  the  MeSH  criteria)  related  to  each  COPD  included  in  the
study:  asthma,  CF,  RWI,  BPD,  PCD,  NCFB,  BO,  and  PB.
COPDC: an overview
The  ﬁrst  important  feature  of  COPDC  is  that  their  clinical
manifestations  and  prevalence  are  more  common  in  cer-
tain  age  groups,  as  shown  in  Fig.  1.  The  second  is  that
interactions  between  the  genetic  component  and  environ-
mental  aggressions  initiate  or  exacerbate  them,  as  shown
in  Fig.  2.  The  main  differences  and  similarities  between
the  COPDC  are  shown  in  Table  1.  The  third  characteristic
of  COPDC  is  that  they  evolve  with  PE,  predominantly  infec-
tious  (CF),  inﬂammatory  (asthma),  and  mixed  (asthma  and
viruses/bacteria).
Infectious  PE  caused  by  bacteria  are  different  in
healthy  children  when  compared  with  those  with  COPDC.
Streptococcus  pneumoniae, Haemophilus  inﬂuenzae  and
Staphylococcus  aureus, which  have  high  virulence,  are  com-
mon  causes  of  pneumonia  in  previously  healthy  individuals
without  COPDC  and  require  treatment  with  low-spectrum
antibiotics  (e.g., penicillin  and  amoxicillin),  but  cause  short-
term  mortality.  In  contrast,  many  patients  with  COPDC,
especially  those  with  CF,  PCD,  and  NCFB,  have  PE  caused
by  low-virulence  bacteria  (Pseudomonas  aeruginosa  (PA),
Burkholderia  cepacia  complex,  Stenotrophomonas  mal-
tophilia  and,  Achromobacter  xylosoxidans), which  cause
long-term  mortality;  however,  they  require  broad-spectrum
antibiotics  such  as  aminoglycosides,  meropenem,  and  third-
generation  cephalosporins  (Fig.  3).
Due  to  the  characteristics  of  COPDC,  several  guidelines
and  systematic  reviews  for  the  diagnosis  and  management
of  the  disease  have  been  proposed  for  both  periods  between
crises  and  PE  of  most  COPDC,  aiming  to  prevent  further  dete-
rioration  of  pulmonary  function  and  damage  (Fig.  4).6,15--27
r
t
m
mS13
sthma
sthmatic  individuals  who  manifested  the  disease  early  in
ife  persist  with  symptoms,  and  evidence  suggests  that
sthma  severity  in  childhood  predicts  the  disease  severity
n  adulthood.28 Recent  guidelines  emphasize  difﬁculties  for
he  deﬁnitive  diagnosis  of  asthma  in  children  younger  than
 years,  where  several  COPDC  phenotypes  have  been  iden-
iﬁed.
For  children  older  than  5  years,  asthma  diagnosis  is
ased  on:  (1)  a  history  of  acute  respiratory  failure  crises
hat  improve  with  short-acting  bronchodilators  (SABA);
2)  increased  serum  IgE  in  the  absence  of  parasitic
iseases,  eosinophilia,  and  positive  immediate  hypersensi-
ivity  skin  tests  for  airborne  allergens;  (3)  spirometry  and
easurement  of  bronchial  hyperresponsiveness  (BHR)  to
ethacholine  challenge.  The  diagnosis  can  be  made  with  the
solated  presence  and/or  combination  of  the  above  items  1;
 +  2;  1  +  3;  or  1  +  2  +  3.
Numerous  factors  have  been  associated  with  increased
isk  of  developing  asthma  in  adolescence,  of  which  the
ollowing  should  be  mentioned:  personal  or  family  history
f  allergy,  male  gender,  obesity,  pollution,  exposure  to
igarette  smoke,  RWI,  severe  infection  by  respiratory  syn-
ytial  virus  (RSV),  pneumonia  in  the  ﬁrst  year  of  life,  RWI
everity,  altered  pulmonary  function,  and  BHR.8,29--31
There  is  no  speciﬁc  treatment  for  asthma,  and  it  is  prefer-
ble  to  use  the  term  management  for  the  tools  used  to
ttain  disease  control.  The  main  objectives  for  outpatient
anagement  are:  (i)  make  chronic  symptoms  minimal  or
onexistent;  (ii)  decrease  the  intensity  and  the  number
f  PE;  (iii)  maintain  lung  function  as  close  as  possible  to
ormal  levels;  (iv)  maintain  normal  levels  of  daily  activi-
ies,  including  physical  exercises;  (v)  prevent  the  adverse
ffects  of  anti-asthmatic  drugs;  (vi)  prevent  disease  progres-
ion  to  irreversible  airﬂow  limitation;  (vii)  prevent  asthma
ortality.6,15--20 The  main  medications  to  control  asthma  are
nhaled  corticosteroids  (IC).
The  classiﬁcation  of  the  clinical  pictures  and  respective
reatment  steps  are  listed  below:
teps  in  the  treatment  of  asthma
Step  1)  Individuals  with  intermittent  asthma,  characterized
y  normal  spirometry  and  periods  between  crises  lasting
onger  than  1  month  without  exacerbations  in  the  last  year,
hould  receive  SABA.  (Step  2)  Continued  use  of  IC  at  low
oses  and  rescue  SABA  during  crisis.  (Step  3)  Continued  use
f  low  doses  of  IC  +  long-acting  beta  agonists  (LABA)  with
ABA  for  crises  or  IC  +  formoterol  for  both  maintenance
nd  control.  (Step  4)  IC  +  formoterol  for  maintenance  and
rises  or  medium  or  high  doses  of  IC  +  LABA  and  SABA,  if
ecessary.  (Step  5)  Refer  patient  to  a  center  specialized  in
sthma  treatment  for  difﬁcult-to-control  disease:  consider
ral  steroids  and  anti-IgE  (omalizumab).  Consider  oral
orticosteroids  in  severe  PE  and  if  the  patient  had  previous
evere  PE.6,15--20
Medications  and  steps  are  modiﬁed  to  the  next  step  or
evert  to  the  previous  step,  depending  on  whether  or  not
he  asthma  is  controlled.  A  decrease  in  management  steps
ust  occur  if  the  asthma  is  well  controlled  for  at  least  3
onths.
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Table  1  Main  clinical  and  pathophysiological  characteristics  of  COPDC  versus  COPD  in  adults.
COPDC
characteristics
ASTHMA  RWIs  BPD  BO  and  PIBO  CF  BP  PCD  NCFB  Classic  adult
COPD
Symptom  onset  Before  5  years  of
life
<2  years  Newborn  <3  years  <2  years  in
classical  forms
CHD:  <5  years
Asthma:  >5
years
First  year  of
life
After  the
second  year  of
life
Adults  >40
years
Age of  higher
prevalence
Childhood  1--2  years  First  year  of
life
Childhood
and
adolescence
Up  to  30  years  CHD:  <5  years
Asthma:  >5
years
Childhood  and
adolescence
Childhood  and
adolescence
After  40  years
Main clinical
marker
Family  history  of
asthma,  personal
atopy  and  positive
response  to  BD
Infection  by
respiratory
viruses
(RSV  and
RV)
Prematurity
Oxygen  use
Virus  Chronic
colonization  of
the airways  by
Pseudomonas
aeruginosa  and
pancreatic
failure
Elimination  of
bronchial  casts
with  sputum
Suppurative
infections  of
the  upper  and
lower  airways
Recurrent
infections  and
chronic  cough
Smoking,
emphysema,
and  biomass
smoke
Prevalence High
(5--30%)
High
(15--60%)
High;  26%  in
VLBW
infants
Low
?
Low.  Classiﬁed
as  rare  disease.
1:2500--1:10,000
live  births
Low
?
Low
?
Low
?
6--15.8%  of  the
population
older  >40  years
Bases for
diagnosis
Spirometry,
positive  response
to  BD,  IgE,  and
skin  prick  test
>3  episodes
of  wheezing
in infancy
and  positive
API
Prematurity
and  oxygen
therapy  for
more  than
28  days  in
early  life
Lung  biopsy,
HRCT  and
lung
perfusion
scintigraphy
NBS  with  a
positive  IRT,
chloride
>60  mEq/L  in
sweat,  two
mutations  in
the  CFTR  gene
Airway  cast
expectoration
and
bronchoscopy
Dextrocardia,
chronic
sinusitis,
pneumonia  and
recurrent  URTIs
HRCT  Smoking,
emphysema
and  alpha1
antitrypsin
deﬁciency
Genotype Many
chromosomes  and
polymorphisms
Many  chro-
mosomes
and  poly-
morphisms
Little  known  Little  known  Autosomal
recessive  with
alterations  in
CFTR  gene
located  on
chromosome  7.
6  classes  of
mutations.
Many
polymorphisms
Unknown  Autosomal
recessive
Depends  on  the
etiology
--
Phenotype Several  Several  M,  Mo,  S  Constrictive
proliferative
Many.  With  and
without
pancreatic
failure
Depending  on
the  etiology,
the  bronchial
mold  has  a
different
composition
With  and
without
dextrocardia
Depends  on  the
etiology
With  and
without  asthma
Chronic
 obstructive
 pulm
onary
 diseases
 in
 children
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Table  1  (Continued)
COPDC
characteristics
ASTHMA  RWIs BPD  BO  and  PIBO CF  BP  PCD  NCFB  Classic  adult
COPD
BAL  Eosinophils  Neutrophils
and/or
eosinophils
Neutrophils  Neutrophils  Neutrophils  Mucin  and
ﬁbrin
Neutrophils  Neutrophils  Neutrophils  and
macrophages
Markers in
lymphocytes
High  CD4/CD8 Varies
whether  the
BAL  is
eosinophilic
or
neutrophilic
?  ?  ?  ?  ?  Depends  on  the
etiology
High  CD8/CD4
Inﬂammatory
mediators
IL4, IL5,  IL9,  IL13,
TNF-, GM-CSF
Varies
whether  the
BAL  is
eosinophilic
or
neutrophilic
TNF-,  IL-1,
IL-6,  IL-10
IL1,  IL6,
IL8,  TNF-,
and  NFk
IL8  ?  ?  Depends  on  the
etiology
IL8,  LTB4,
proteases,
MMP9,  TNF-,
TGF-1
Main causes  of
PE
Viruses  and
aero-allergens
Viruses Viruses Viruses Gram-negative
bacteria
Inﬂuenza
H1N1
?
Viruses  and
bacteria
Bacteria  and
viruses
Viruses  and
bacteria
Response to  BD Yes Little  known Unknown  Rare  Rare  ?  ?  No  Low
Obstruction Intermittent  in  the
mild  cases  and
ﬁxed  in  severe
cases
Intermittent  Fixed  Fixed  Fixed  Intermittent  Fixed  Fixed  Fixed
Survival/
Mortality
Long/low Long/low  Depends  on
the  severity
and
gestational
age
Depends  on
severity
<40  years  --
class  I--III
mutations.
>40  years  --
class  IV--VI
mutations
Low/high  <40  years  Depends  on  the
age  of  onset
and  etiology
Depends  on  the
severity.
High  mortality
in  the  elderly
Evolution to
restrictive  lung
diseases
Rare  Rare  Rare  Frequent  Frequent  Rare  Frequent  Frequent  Frequent
Evolution to
lung
transplantation
No  No  No  Rare  Yes No  Yes  Yes  No
Comorbidities Allergic  rhinitis,
atopic  dermatitis
and  GERD
GERD  GERD  and
prematurity
Severe
adenovirus
infection
Pancreatic
failure,
depression,
diabetes,  and
osteoporosis
CHD,  asthma,
lymphatic
disease,  ABPA
Azoospermia
and  chronic
rhinosinusitis
?  Asthma  and
GERD
S16
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Table  1  (Continued)
COPDC
characteristics
ASTHMA  RWIs  BPD  BO  and  PIBO  CF  BP  PCD  NCFB  Classic  adult
COPD
Treatment  IC;  SABA;  LABA;
Montelukast;
omalizumab
IC;  SABA;
Montelukast
IC;  SABA;
Sildenaﬁl
and  PH
Diuretics
IC;  SABA;
LABA;
corticoids;
oxygen;
tiotropium
bromide
Mucolytics;  IA;
digestive
enzymes,  IC;
SABA;  LABA;
corticosteroids;
tiotropium;
Oxygen
bronchoscopy;
mucolytics  and
antiﬁbrinolytics
Mucolytics,  IA;
IC;  SABA;  LABA;
corticosteroids
and  oxygen
Mucolytics;  IA
IC;  SABA;  LABA;
corticosteroids;
oxygen;
macrolides
IC;  SABA;  LABA;
corticosteroids;
Tiotropium  and
oxygen
Perspectives Early intervention
in  utero  and  early
in life  at  risk
populations.
Prophylaxis
against  RSV  and  RV.
Immunomodulation
with  prebiotics,
probiotics  and
bacterial  lysates.
Prevention  of
allergic
sensitization.
Permissive
hypercapnia
and
improved
care  to
VLBW
infants
Palivizumab;
genes  and
polymor-
phisms;
respiratory
virus
vaccines
Corrections
by
potentiators
and  carriers
of  CFTR
protein  and
new  tests
for  the
diagnosis  of
atypical
forms
Multicenter
studies,
national
registries
Genetic  studies
and  early
diagnosis
Prophylaxis
against  viruses
Avoid  smoking
Asthma  control
?, unknown; ABPA, allergic bronchopulmonary aspergillosis; IA, inhaled antibiotics; BD, bronchodilator; NCFB, non-cystic ﬁbrosis bronchiectasis; BO, bronchiolitis obliterans; PIBO,
post-infectious bronchiolitis obliterans; PB, plastic bronchitis; CHD, congenital heart disease; IC, inhaled corticosteroids; CD4, CD4 molecule; CD8, CD8 molecule; CFTR, cystic ﬁbro-
sis transmembrane regulator; BPD, bronchopulmonary dysplasia; PCD, primary ciliary dyskinesia; COPD, chronic obstructive pulmonary disease; COPDC, chronic obstructive pulmonary
disease in childhood; GERD, gastroesophageal reﬂux disease; PE, pulmonary exacerbation; CF, cystic ﬁbrosis; GM-CSF, granulocyte macrophage-colony stimulating factor; PH, pulmonary
hypertension; IgE immunoglobulin E; IL, interleukin; API, asthma predictor index; URTI, upper respiratory tract infection; LABA, long-acting beta-agonists; BAL, bronchoalveolar lavage;
LTB4 leukotriene B4; M, mild; Mo, moderate; S, severe; MMP, matrix metallopeptidase; NF-kB, NF-kappaB; VLBW, very low birth weight; RSV, respiratory syncytial virus; RV, rhinovirus; SABA,
short-acting beta agonists; RWI, recurrent wheezing in infants; HRCT, high-resolution computed tomography; SPT, skin prick test; TGF, transforming growth factor; IRT, immunoreactive
trypsinogen; NBS, newborn screening test; TNF, tumor necrosis factor; RSV, respiratory syncytial virus.
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Figure  1  Age  of  onset  and  higher  prevalence  of  major  chronic  obstructive  pulmonary  disease  in  children  (COPDC)  compared  with
stic  ﬁ
stic  
p
n
m
echronic obstructive  pulmonary  disease  (COPD)  in  adults.  CF,  cy
monary dysplasia;  PCD,  primary  ciliary  dyskinesia;  NCFB,  non-cy
obliterans; m,  month;  y,  year.
It  is  essential  to  verify  at  all  consultations,  whether
the  asthma  is  controlled  or  not,  from  the  clinical  and/or
functional  point  of  view,  based  on  six  parameters:  (i)
nocturnal  signs  and  symptoms;  (ii)  daytime  signals  and
symptoms;  (iii)  signs  and  symptoms  with  physical  exercise
or  limitation  in  daily  activities;  (iv)  PE;  (v)  need  for  relief
medication  (SABA);  (vi)  changes  in  lung  function.  Hence,
asthma  is  considered  controlled  when  all  parameters  are
normal;  it  should  be  classiﬁed  as  partially  controlled  in  the
(
e
m
r
Genetic factors:
mutations and
polymorphisms
Non-controlled
inflammation
Lung damage,
loss of lung function
Physiopathological consequences
Structural damage, remodeling,
and alveolar involvement
Poor quality of life
Airflow limitation, lung hyperinflation,
and increased respiratory effort
COPDC
Figure  2  Interactions  of  causes,  effects,  and  clinical  outcomes  ofbrosis;  RWIs,  recurrent  wheezing  in  infants;  BPD,  bronchopul-
ﬁbrosis  bronchiectasis;  PB,  plastic  bronchitis;  BO,  bronchiolitis
resence  of  one  or  two  altered  parameters;  and  ﬁnally,
on-controlled  asthma  should  be  considered  when  three  or
ore  parameters  are  altered.
The  absence  of  control  of  signs  and  symptoms,  frequent
xacerbations,  previous  admission  to  an  intensive  care  unit
ICU),  low  values  of  forced  expiratory  volume  in  1  s  (FEV1),
xposure  to  tobacco  smoke,  and  need  to  use  high-dose
edications  are  characteristics  associated  with  increased
isk  of  adverse  events  in  the  future.  By  deﬁnition,  an
Controlled
inflammation
Good quality
of life
CURE?
Few symptoms and
mild clinical pictures
Environmental factors:
pollution, viruses,
bacteria, and allergens CAUSES
E
F
F
E
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Mortality
Need for
treatment with
Isolated
microorganisms
Microorganism
virulence High
Previously healthy children
without COPDC
Low
Children with COPDC
Small-spectrum
antibiotics (eg. Penicillin,
amoxicillin)
Broad-spectrum antibiotics
(eg. Aminoglycosides,
meropmemicos,
d-cephalosporins)
Pseudomonas aeruginosa
burkholderia cepacia (complex)
stenotrophomonas maltophilia
achromobacter xylosoxidans
fungi
Streptococcus pneumoniae
Haemophylus influenzae
Staphylococcus aureus
Short-term Long-term
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(igure  3  Bacterial  acute  pulmonary  exacerbations  in  chronic
n previously  healthy  children.
xacerbation  at  any  week  is  indicative  of  non-controlled
sthma  and  also  of  the  need  for  review  of  the  maintenance
reatment.16,17
In  the  management  of  patients  with  asthma,  the
ollowing  are  essential:  (i)  management  supported  by
vidence-based  medicine;  (ii)  to  perform  the  diagnosis  and,
r
a
a
a
COPD
Defined diagnosis
Controlled
•  Of lung function
•  Of lung damage
Longterm follow-up to periodically
evaluate control and
evolution:
Refer to
reference center Management acco
to guidelines
Figure  4  Control  or  non-control  of  chronic  obstructive  pulmructive  pulmonary  disease  in  children  (COPDC)  and  pneumonia
f  possible,  the  phenotype  (e.g.,  allergic  and  non-allergic);
iii)  to  exclude  and  treat  comorbidities;  (iv)  to  assess  and
ecommend  the  adequate  use  of  prescribed  drugs;  (v)  to
ssess,  advise,  and  encourage  treatment  adherence;  (vi)  to
ssess  and  advise  about  environmental  prophylaxis;  (vii)  to
ssess  and  advise  on  the  triggering  factors;  (viii)  to  educate
C
Non-controlled
Assess:
Adherence, comorbidities, correct use of
medications, and associated risk factors
Assess complications of non-controlled disease:
•  In the short term: acute exacerbations
•  In the long term: remodeling
•  Risk of comorbidities
•  Risk of side effects of medications
rding Seek diagnosis
No diagnosis
onary  disease  in  children  (COPDC)  based  on  diagnosis.
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patient’s  caregivers  about  asthma  and  the  factors  inﬂuenc-
ing  it;  (ix)  to  give  instructions  on  the  adequate  use  of  devices
for  administration  of  metered-dose  and  dry  powder  inhalers;
(x)  instructions  for  patients  to  be  able  to  recognize  when
asthma  control  is  deteriorating  and  what  medications  to
use,  when  it  occurs;  (xi)  to  identify  non-controlled  patients
and  causes  of  lack  of  control;  (xii)  to  advise  that  inhaled
medications  should  be  used  with  spacers;  (xiii)  to  advise
on  the  hygiene  of  spacers,  which  must  be  washed  and  left
to  soak  in  water  with  detergent;  (xiv)  LABA  must  not  be
used  in  children  younger  than  4  years;  (xv)  SABA  are  the
agents  of  choice  in  PE;  (xvi)  IC  alone  or  associated  with
bronchodilators  are  the  basis  of  asthma  treatment;  (xvii)
children  younger  than  6  years  can  use  inhaled  medication
with  spacer  and  those  older  than  6  years  can  use  dry  pow-
der  inhalers;  (xviii)  to  assess  pulmonary  function  regularly;
(xix)  to  advise  on  the  need  for  long-term  medical  care;
(xx)  omalizumab  should  be  prescribed  in  reference  cen-
ters  for  the  management  of  patients  with  difﬁcult-to-control
asthma.
Recurrent wheezing in infants (RWI)
There  are  several  phenotypes  and  risk  factors  (RF)  for  RWI,
creating  difﬁculties  for  asthma  diagnosis  and  resulting  in
an  excessive  assessment  for  comorbidities.32--37 The  main  RF
include:  presence  of  familial  and/or  personal  allergy,  early
sensitization,  severe  RSV  infection,  maternal  smoking  during
pregnancy,  and  unfavorable  airway  geometry.  Other  impli-
cated  RF  are:  genetic  variants,  excessive  hygiene,  Western
lifestyle,  pollution,  gastroesophageal  reﬂux  disease  (GERD),
low  socioeconomic  status,  urban  environment,  antibiotic
use,  diet,  few  siblings,  ethnicity,  male  gender,  and  atten-
dance  of  daycare.38
Exposure  to  maternal  smoking,  both  intrauterine  and  in
the  early  years  of  life,  has  contributed  to  increased  inci-
dence  and  severity  of  childhood  and  adult  asthma,  COPD
in  adults,  lung  function  deﬁcits,  lung  hypoplasia,  respira-
tory  tract  infections,  and  higher  predisposition  to  sudden
death  syndrome.39--41 Respiratory  viruses  are  the  main  RF  for
asthma  and  RWI  initiation  or  exacerbation:  (i)  some  viruses
B
B
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Table  2  Asthma  Predictive  Index  (API)  by  Castro-Rodriguez  et  al.
API  criteria  Original  API1
General
Convincing  API:  more  than  three  episodes  of  wheez
during  the  ﬁrst  3  years  of  life  with  a  major  criterio
minor.
Less convincing  API:  less  than  three  episodes  of  wh
during  the  ﬁrst  3  years  of  life  with  a  major  criterio
minor.
Major History  of  parental  asthma
Atopic  dermatitis
Minor Allergic  rhinitis  diagnosed  by  physician
Wheezing  unrelated  to  colds
Eosinophilia  ≥  4%
API, asthma predictive index.S19
nitiate  asthma;  (ii)  the  more  severe  the  respiratory  infec-
ion,  the  higher  the  likelihood  of  developing  asthma;  (iii)
iruses  cause  PE  in  children  and  adults  with  established
sthma.42
The  diagnosis  of  asthma  in  infants  is  a  major  chal-
enge  for  clinicians;  to  attain  a  diagnosis  with  a  high
egree  of  suspicion,  the  presence  of  allergy  should  be
nvestigated,  as  it  is  a  persistent  asthma  predictor.  The
nvestigation  of  severe  COPDC  in  children  younger  than
 years  may  require  many  tests,  including  high-resolution
omputed  tomography  (HRCT),  lung  function  assessment,
ellular  and  humoral  immunity  evaluation,  bronchoscopy,
ronchoalveolar  lavage,  24-h  esophageal  pH-metry,  endo-
ronchial  biopsy,  mutation  screening,  and  sodium  and
hloride  sweat  measurements.35 In  contrast,  no  investi-
ation  is  necessary  for  most  of  RWI,  because  it  cannot
ifferentiated  with  certainty  whether  the  future  course  of
he  RWI  will  be  persistent  asthma  or  transient  wheezing.43
Some  asthma  predictive  indices  (APIs)  have  been  devel-
ped  to  identify  children  with  RWI  and  at  risk  for  asthma
fter  6  years  of  age  (Table  2).38,44 Some  authors  have  men-
ioned  methodological  and  practical  limitations  of  APIs,
uggesting  that  they  have  low  capacity  and  poor  sensitiv-
ty  to  predict  asthma  at  school  age,45,46 and  that  although
hey  are  simple  and  easy-to-apply  tools,  they  have  not
een  sufﬁciently  validated.  According  to  these  authors,
redicting  asthma  using  simple  clinical  models  is  virtually
mpossible.45,46
Although  most  of  the  scientiﬁc  community  is  favorable
o  the  use  of  APIs,47,48 the  search  for  clinical  and/or  labora-
ory  markers  for  the  diagnosis  of  asthma  in  RWI  and  children
ounger  than  5  years  remains  a  rich  area  for  future  stud-
es.  Infants  and  preschoolers  with  RWI  or  asthma  have  less
E,  and  show  symptom  and  lung  function  improvement  when
reated  with  IC.49--51
The  dosages  of  the  main  IC  used  in  COPDC  are  shown  in
able  3.ronchiolitis obliterans (BO)
ronchiolitis  obliterans  (BO)  is  a  predominantly  neutrophilic
OPDC  with  high  levels  of  proinﬂammatory  cytokines,
44 and  Guilbert  et  al.38
Modiﬁed  API38
ing/year
n  or  two
The  child  must  have  a  history  of  four  or  more
episodes  of  wheezing.  At  least  one  episode
veriﬁed  and  conﬁrmed  by  a  physician.
eezing/year
n  or  two
History  of  parental  asthma
Atopic  dermatitis  diagnosed  by  physician
Allergic  sensitization  to  one  or  more
aeroallergens
Sensitization  to  cow’s  milk,  egg,  or  peanut
Wheezing  unrelated  to  colds
Eosinophilia  ≥  4%
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Table  3  Low,  medium,  and  high  daily  doses  of  inhaled  corticosteroids  (IC)  in  asthma  (Global  Initiative  for  Asthma  --  GINA)  and
in chronic  obstructive  pulmonary  disease  in  childhood.
Inhaled  corticosteroids  Daily  doses  in  children  younger  than  5  years  Daily  doses  (6--11  years)
Low  Medium  High  Low  Medium  High
Beclomethasone
Dipropionate  HFA
100  50--100  >100--200  >200
Budesonide spray  200  100--200  >200--400  >400
Nebulized budesonide 250--500  >  500--1000  >  1000  250--500  >500--1000  >1000
Fluticasone propionate
HFA  spray
100  100--200  >250--500  >500
Fluticasone propionate
dry  powder
100--200 >250--400 >400
Ciclesonide  160  80  >80--160  >160
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cMometasone  There  are  no  studies  
Triamcinolone  There  are  no  studies  
ronchial  remodeling,  and  ﬁbrosis  in  the  small  airways.
hen  the  etiology  is  infectious,  it  is  called  post-infectious
O  (PIBO).  Most  often,  PIBO  is  caused  by  previous  infec-
ion  caused  by  adenovirus,  but  inﬂuenza,  measles,  RSV,  and
ycoplasma  pneumoniae  are  also  observed.  Latin  American
ountries  have  the  highest  rates  of  this  disease.27,52--62
Studies  have  shown  that  lung  function  remains  altered
ith  an  obstructive  pattern  and  air  trapping  during  child-
ood.  These  patients  are  often  hospitalized  due  to  recurrent
espiratory  infections.  Patients  show  slight  improvement
ver  the  years.54,62
Five  criteria  are  essential  for  the  diagnosis  of  PIBO:  (i)  his-
ory  of  acute  viral  bronchiolitis  and  viral  pneumonia  before
he  age  of  3;  (ii)  evidence  of  persistent  airway  obstruction
fter  the  acute  event,  identiﬁed  by  physical  examination
nd/or  lung  function,  which  is  not  responsive  to  at  least
 weeks  of  systemic  corticosteroids  associated  with  bron-
hodilator;  (iii)  radiological  ﬁndings  of  obstruction  such  as
yperinﬂation,  atelectasis,  bronchial  wall  thickening,  and
ronchiectasis;  (iv)  mosaic  perfusion  and  air  trapping  on
RCT;  (v)  exclusion  of  other  COPDC.27,60
Among  the  causes  of  BO  are:  drugs,  association  with
tevens--Johnson  syndrome,  collagenoses,  irradiation,  for-
ign  body  or  gastric  content  aspiration,  and  graft  vs.  host
isease  after  transplantation.
The  deﬁnitive  diagnosis  of  BO  is  made  through  anato-
opathological  examination  of  fragments  obtained  from
ung  biopsy.  BO  is  classiﬁed  as:  (i)  proliferative  BO,  charac-
erized  by  airway  obstruction  by  polyps  and/or  granulation
issue  in  the  lumen  of  bronchioles;  or  (ii)  constrictive  BO,
haracterized  by  peribronchial  inﬂammation  and  ﬁbrosis.58
s  the  lung  biopsy  is  an  invasive  test,  most  studies  perform
he  diagnosis  based  on  clinical  history  and  HRCT,  spirometry,
nd  perfusion  scintigraphy  with  technetium.  Alterations
n  HRCT  include  wall  thickening  and  bronchiole  obliter-
tion  and,  with  the  disease  progression,  bronchiectasis,
ronchial  wall  thickening,  mosaic  perfusion,  air  trapping,
educed  lung  volume,  and  decreased  diameter  of  hilar  and
eripheral  vessels  are  observed.27,59There  is  no  speciﬁc  treatment  for  BO.  Oxygen  therapy
s  essential  in  some  patients,  mainly  after  ICU  discharge
or  severe  acute  viral  bronchiolitis  (AVB)  and  in  patients
ho  develop  chronic  hypoxemia.  Contact  prophylaxis  with
i
n
b110  220  ≤  440  440  or  more
400--800  >800--1200  >1200
ntra  and  extra-domestic  pollutants,  reduction  of  exposure
o  active  and  passive  smoking,  and  anti-pneumococcal  and
nﬂuenza  vaccination  are  important  steps  for  BO  manage-
ent.  In  the  early  phases  of  the  disease,  some  patients
ay  beneﬁt  from  systemic  corticosteroid  therapy.  Bron-
hodilators,  antibiotics  in  infectious  exacerbations,  surgery
or  resection  of  ﬁxed  collapsed  lung,  and  lung  transplant
ave  also  been  used.27
rimary ciliary dyskinesia (PCD)
rimary  ciliary  dyskinesia  (PCD)  is  an  autosomal  recessive
OPDC  caused  by  several  alterations  in  airway  cilia  anatom-
cal  and  functional  structure,  resulting  in  inﬂammation  and
nfection,  with  an  incidence  of  1:4000--40,000  live  births.
aterality  defects  in  the  thoraco-abdominal  organs  occur  in
bout  50%  of  patients  with  PCD,  and  most  have  situs  inversus
otalis  (Kartagener  syndrome).24,63--66
PCD  should  be  suspected  in  children  with:  (i)  situs  inver-
us  totalis  or  other  laterality  defect  in  thoraco-abdominal
rgans;  (ii)  recurrent  upper  (otitis,  sinusitis)  and  lower
espiratory  tract  infections  (pneumonia,  abscesses)  and
hronic  respiratory  tract  diseases  of  undeﬁned  etiology
bronchiectasis,  chronic  cough,  atelectasis,  and  middle  lobe
yndrome);  (iii)  neonatal  respiratory  distress  syndrome  of
ndeﬁned  causes;  (iv)  diagnosis  of  PCD  in  other  family  mem-
ers;  (v)  congenital  heart  disease,  especially  if  associated
ith  heterotaxia,  and  with  chronic  and  repeated  infections
f  the  lower  and  upper  airways.24,67
Clinical  manifestations  and  alterations  in  PCD  vary
ccording  to  age25: in  the  prenatal  period,  ultrasound  may
eveal  mild  fetal  cerebral  ventriculomegaly,  heterotaxia  and
itus  inversus  totalis  (approximately  25%  of  individuals  with
itus  inversus  totalis  have  PCD).  PCD  prevalence  in  patients
ith  heterotaxia  remains  unknown.  In  the  neonatal  period,
5%  of  full-term  newborns  with  PCD  have  respiratory  dis-
ress,  requiring  supplemental  oxygen  for  days  or  weeks.
ome  have  continuous  rhinorrhea,  heterotaxia,  and  hydro-
ephalus.During  childhood,  chronic  productive  cough  is  observed,
n  association  with  atelectasis  and/or  recurrent  pneumo-
ia,  atypical  asthma  that  does  not  respond  to  treatment,
ronchiectasis,  NCFB,  nasal  polyps,  chronic  rhinosinusitis,
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hearing  impairment,  and  chronic  otitis.  In  adolescence
and  adulthood,  bronchiectasis,  chronic  mucopurulent  spu-
tum,  digital  clubbing,  spirometry  with  progressive  or  mixed
obstructive  ventilatory  pattern,  nasal  polyposis,  and  halito-
sis  can  be  observed,  as  well  as  infertility  in  men  (50%)  and
ectopic  pregnancy  in  women.
Diagnosis  is  based  on  clinical  and  radiological  alter-
ations,  nasal  nitric  oxide  levels,  ciliary  beat  pattern  at  video
microscopy,  structural  alterations  of  the  cilia  by  electron
microscopy,  and  detection  of  mutations.  Only  50--60%  of  PCD
patients  have  a  known  mutation.25,68,69
CF  evolves  with  secondary  ciliary  dyskinesia,  whereas  in
PCD  it  is  primary;  the  management  of  pulmonary  disease  in
these  two  diseases  is  virtually  identical.25
Cystic ﬁbrosis (CF)
CF  is  an  autosomal  recessive  disease  caused  by  mutations
in  the  CFTR  (cystic  ﬁbrosis  transmembrane  regulator)  gene,
7q31.2  region,  which  has  more  than  2000  identiﬁed  muta-
tions,  divided  into  six  classes  regarding  the  production  and
function  of  the  CFTR  protein.  The  qualitative  or  quantitative
absence  or  dysfunction  of  CFTR  causes  physiopathological
changes  in  several  organs.  Most  of  CF  morbidity  and  mor-
tality  is  caused  by  manifestations  in  the  respiratory  and
digestive  tracts.70--73
It  is  currently  known  that  in  Class  I,  II,  and  III  muta-
tions,  the  disease  starts  before  symptom  onset,  constituting
a  major  factor  for  early  intervention  and  more  aggressive
treatments,  showing  promising  results  in  reducing  lung  func-
tion  damage  and  deterioration,  with  consequent  increased
survival.70--73
Availability  of  newborn  screening,  sweat  testing,  CFTR
gene  mutation  screening,  medications,  and  possible  use
of  correctors,  enhancers,  and  stabilizers  (for  some  muta-
tions)  of  the  CFTR  protein  are  concrete  facts  in  the  last
decade.  The  consequence  is  that  the  survival  of  these
patients  is  increasingly  higher.73 Lung  damage  and  decreased
lung  function  are  progressive,  and  depend  on  the  mutation,
gender,  polymorphisms,  treatment  availability  and  adher-
ence,  early  treatment,  comorbidities,  and  care  in  reference
centers.74--76
The  physiopathology  of  COPD  in  CF  can  be  understood
with  the  following  six  events  (6D):  (i)  defect  in  the  CFTR
gene;  (ii)  impairment  or  absence  of  the  CFTR  protein;  (iii)
dehydration  of  the  airway  surface  liquid;  (iv)  defect  in
bacterial  clearance  in  the  airways;  (v)  secondary  ciliary
dyskinesia;  (vi)  destruction  of  the  airway  epithelium.77
To  attain  the  diagnosis  of  CF  after  neonatal  screening,
alterations  in  the  gene  and  or  CFTR  protein  should  be
veriﬁed.  The  CFTR  gene  is  studied  through  the  analysis  of
mutations  and  polymorphisms.  The  CFTR  protein  function
and/or  presence  can  be  assessed  in  the  sweat  glands  (sweat
test,  evaporimetry,  difference  of  potential,  and  pH)  nasal
epithelium,  salivary  glands,  and  digestive  tract.78,79
Diagnosing  or  ruling  out  CF  is  not  always  easy,  even
after  comprehensive  testing,  particularly  in  adolescents  and
adults  with  classes  IV,  V,  and  VI  mutations,  which  cause  non-
classical  forms  and  are  often  associated  with  rare  mutations,
threshold  levels  of  chloride  in  sweat,  late-onset  clinical
manifestations,  and  atypical  symptoms.80
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As  CF  affects  many  organs,  its  management  is  complex.
he  service  must  have  interdisciplinary  teams  with  several
ealth  care  professionals,  physical  therapy,  medical  exam-
nations,  frequent  visits  to  the  hospital,  and  use  of  daily,
epetitive  medications,  which  are  sometimes  complicated
nd  costly.81
Patients  with  CF  are  highly  susceptible  to  chronic  lung
nfection  by  PA.  PA  acquisition  occurs  very  early  and  is
elated  to  lung  function  deterioration  and  worse  CF  progno-
is;  hence,  intensive  treatment  against  PA  is  crucial  in  the
anagement  of  CF.
Other  bacteria  frequently  found  in  the  airways  of  CF
atients  and  that  determine  the  lung  function  damage
nd  deterioration  include  S.  aureus, H.  inﬂuenzae, PA,
.  cepacia  complex,  S.  maltophilia, and  Achromobacter
pecies.  Non-tuberculous  Mycobacteria  (NTM)  and  other
naerobic  bacteria  and  fungi  are  found  less  frequently,
nd  tend  to  appear  at  the  more  advanced  stages  of  lung
isease.82,83
Inhaled  antibiotics  (IA)  are  essential  for  the  treatment
f  chronic  lung  infections  in  CF.  The  increased  survival  in
atients  with  CF  in  recent  decades  can  be  partly  attributed
o  the  use  of  IA.  They  have  higher  deposition  at  the  infection
ite  and  less  risk  of  systemic  side  effects  than  parenteral
herapy,  decrease  PE,  and  improve  quality  of  life  and
pirometry.84,85
CF  patients  with  chronic  lung  infection  by  PA  should
eceive  long-term,  nebulized  anti-pseudomonal  therapy,
nless  there  is  contraindication.  Among  the  IA,  tobramycin
nd  colistin  are  currently  available,  while  aztreonam,  levo-
oxacin,  and  liposomal  amikacin  will  soon  be  available.86
he  administration  of  IA  is  time-consuming  and  is  a  heavy
urden  for  patients.  Treatment  adherence  is  a  signiﬁcant
hallenge.87
The  treatment  of  the  ﬁrst  acquisition  episode,  from
nfection  to  chronic  infection  and  PE  due  to  PA,  are  reasons
or  debates  and  controversies  in  the  literature.88
PA  eradication  protocols  have  demonstrated  antibiotic
fﬁcacy  in  the  ﬁrst  bacterial  isolation;  intensive  treatment
ith  intravenous  antibiotics  in  PE  and  IA  in  the  periods
etween  crises.89--91
It  is  advisable  to  perform  lung  damage  assessment  by
RCT  at  least  every  2  years,  and  pulmonary  function  assess-
ent  by  spirometry  at  least  twice  a  year.
IA,  anti-inﬂammatory  drugs,  corticosteroids,  bron-
hodilators,  and  mucolytics  may  be  necessary  for  the
anagement  of  lung  disease  in  CF.  Auxiliary  measures  have
hown  beneﬁts  with  respiratory  physical  therapy,  regular
xercise,  avoiding  indoor  and  outdoor  pollution,  and  active
nd  passive  smoking.  It  is  crucial  to  include  treatment  adher-
nce  measures  and  continuity  of  care  for  life.  Visits  to  the
eference  center  must  be  monthly  during  the  ﬁrst  year  and
t  least  four  times  a  year  until  adulthood.
Adherence  to  CF  management  varies  between  35  and  75%
nd  is  lower  in  adolescence.  Poor  adherence  to  medica-
ion  worsens  lung  function,  increases  the  frequency  of  PE,
nd  results  in  a  larger  number  of  consultations,  hospitaliza-
ions,  and  costs.  Therefore,  interventions  are  necessary  to
mprove  medication  adherence.81
Many  international  organizations  have  proposed  that  the
anagement  of  lung  disease  in  CF  should  be  directed
y  guidelines  based  on  scientiﬁc  evidence.  Thus,  recent
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ublications  on  the  management  of  COPD  in  CF  can  be
ound,  and  represent  the  ‘‘state-of-the-art’’  for  CF  refer-
nce  centers.82,83,91,92
Recently,  advances  in  the  treatment  of  CF  have  gained
rominence.  Mutations  in  the  CFTR  gene  have  been  widely
dentiﬁed,  and  the  highest  prevalence  of  the  F508del  muta-
ion  has  been  emphasized.  Treatment  for  the  speciﬁc
utation  and/or  class  of  mutations  has  focused  on  the  study
f  new  drugs.  Two  drugs  have  been  used  in  studies  consid-
ring  the  F508del  mutation  in  homozygous  form,  and  results
f  the  association  of  ivacaftor  (increases  opening  of  the
hloride  channel  --  potentiator)  and  lumacaftor  (increases
rotein  number  in  the  epithelium  --  potentiator)  have  shown
ncreased  chloride  transport  when  compared  with  the  values
f  the  individual  drugs.93
ronchopulmonary dysplasia (BPD)
PD  is  a  secondary  COPDC,  and  is  associated  with  prematu-
ity  and  risk  factors  (RF)  related  to  it.  Low  birth  weight,  high
raction  of  inspired  oxygen,  patent  ductus  arteriosus,  high
ntravenous  ﬂuid  volume  values,  mechanical  ventilation  with
igh  pressures,  genetic  susceptibility,  and  infection  in  the
eonatal  period  contribute  to  the  prevalence  and  severity
f  BPD.  This  disease  affects  approximately  30%  of  newborns
ith  birth  weight  less  than  1500  g.94,95
Several  studies  have  shown  that  most  infants  who
evelop  BPD  evolve  with  lung  function  alterations  through-
ut  life.9,96--101
Similar  to  all  COPDC,  BPD  has  no  speciﬁc  treatment.
egarding  the  advances  to  reduce  mortality  in  the  neona-
al  period,  in  recent  decades,  three  factors  have  clearly
roven  to  be  effective:  (i)  corticosteroid  administration  to
regnant  women  with  high-risk  pregnancies;  (ii)  administra-
ion  of  surfactants  to  premature  infants;  (iii)  less  aggressive
entilation  strategies.102,103
The  following  have  also  been  used:  diuretics
furosemide);  bronchodilators;  systemic  corticosteroids  and
C;  vitamin  A;  methylxanthines  (pentoxifylline,  caffeine);
ulmonary  vasodilators  (sildenaﬁl,  inhaled  nitric  oxide);
ate  surfactant  administration;  and  antioxidants  (super-
xide  dismutase),  with  varying  degrees  of  efﬁcacy  in  the
anagement  of  acute  and/or  chronic  BPD.  However,  there
s  little  evidence  of  the  beneﬁcial  actions  of  most  of  these
gents  when  used  in  short-  or  long-term  management  of
PD.102,103
BPD  is  associated  with  a  high  incidence  of  pulmonary
rterial  hypertension  (PAH).  Treatment  with  sildenaﬁl
as  been  associated  with  signiﬁcant  improvement  in
chocardiographic  markers  of  PAH  and  reduced  need  for
xygen.  The  drug  is  well  tolerated.104
ronchiectasis related to diseases other than
F (NCFB)
ronchiectasis  is  an  alteration  that  accompanies  many
OPDC.  It  may  be  associated  with  and  complicate  asthma,
CD,  CF,  BO,  and  NCFB,  and  be  consequent  to  measles,
ertussis,  immunodeﬁciency,  allergic  bronchopulmonary
spergillosis,  inﬂammatory  bowel  disease,  rheumatoid
rthritis,  foreign  body  inhalation,  PCD,  BO,  respiratory
f
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ract  malformation  (e.g.: tracheoesophageal  ﬁstula,  con-
enital  cystic  adenomatoid  malformation)  and  result  from
nﬂammatory  and  infectious  diseases  to  the  airways.  NCFB
ncompasses  several  etiologies  and  degrees  of  severity;  a
lear  cause  cannot  be  established  in  many  patients.105,106
Pulmonary  disease  in  NCFB  is  very  similar  to  CF,  BO,  and
CD.  The  challenge  a  child  with  NCFB  faces  is  the  pursuit  of
 diagnosis.  The  management  is  very  similar  to  that  of  most
OPDC  and  should  be  considered  on  a  case-by-case  basis,
iming  at  patient  comfort  and  clinical  response.107
Although  some  randomized,  controlled,  double-blind  tri-
ls  have  shown  that  prolonged  use  of  macrolides  in  patients
ith  NCFB  improves  quality  of  life  and  reduces  PE  rates,
he  role  of  macrolides  in  NCFB  management  remains  unclear
nd  they  cannot  be  recommended  for  routine  use.  Until
ery  recently,  these  drugs  were  investigated  in  small  trials
f  short  duration,  which  did  not  evaluate  relevant  clinical
utcomes,  such  as  PE  and  quality  of  life.
Long-term  oral  antibiotics  should  not  be  routinely  pre-
cribed.  Macrolides  (or  other  antibiotics)  can  be  considered
or  a  limited  period  of  12--24  months,  especially  in  patients
ith  frequent  exacerbations.4,108,109
lastic bronchitis (PB)
B  is  a rare  COPDC  with  unknown  prevalence  and  etiol-
gy,  with  formation  of  bronchial  molds  of  gelatinous  or  solid
ppearance  in  the  large  airways,  whose  composition  varies,
onsisting  of  mucins,  ﬁbrin,  DNA,  or  eosinophils,  depend-
ng  on  the  PB  etiology.  The  diseases  most  often  associated
ith  PB  are  congenital  heart  disease  and  asthma.  It  has
lso  been  described  in  infection  by  inﬂuenza  virus,  H1N1,
ymphatic  diseases,  allergic  bronchopulmonary  aspergillo-
is,  and  sickle-cell  disease.109 Although  bronchodilators,
orticosteroids,  antibiotics,  mucolytics,  physical  therapy,
ntiﬁbrinolytic  therapy  with  heparin,  and  urokinase  have
een  used,  single  or  repeat  bronchoscopy  is  essential  for
iagnosis  and  treatment.
inal considerations
he  pediatrician’s  actions  are  vital  for  the  management
f  COPDC.  The  clinician  should  suspect  the  disease  in  the
resence  of  signs  and  symptoms  in  order  to  attain  an  early
nd  accurate  diagnosis,  know  the  risk  factors  and  associated
omorbidities,  and  assess  treatment  adherence,  the  correct
se  of  prescribed  drugs,  and  their  side  effects  based  on
ell-deﬁned  management  protocols,  preferably  based  on
peciﬁc  guidelines.
Management  beneﬁts  should  be  assessed  through  the
eduction  in  acute  pulmonary  exacerbations,  increased
uality  of  life,  and  decreased  evolution  of  lung  function
oss  (spirometry,  measurement  of  oxygen  saturation,  lung
learance  index)  and  lung  damage  (HRCT  every  2  years,
f  necessary).  Therefore,  the  sequential  evaluation  of  lung
unction  and  damage  should  be  standardized  and  con-
inuous,  throughout  life.  For  most  COPDC,  monitoring  in
pecialized  reference  centers  by  interdisciplinary  teams
eads  to  better  outcomes.
Chronic  obstructive  pulmonary  diseases  in  children  
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